Global Progressive Multifocal Leukoencephalopathy Treatment Market Poised to Reach USD 1,773.97 Million by 2033 with a Steady CAGR of 3%

Global Progressive Multifocal Leukoencephalopathy Treatment Market

The global progressive multifocal leukoencephalopathy (PML) treatment market is projected to experience stable growth over the next decade, reaching a value of USD 1,773.97 million by 2033, growing at a CAGR of 3% from 2023 to 2033. Currently valued at USD 1,320 million in 2023, the market has witnessed steady progress, registering a CAGR of 2% in the historical period from 2018 to 2022.

PML, a rare and often fatal viral disease of the brain, continues to pose significant healthcare challenges, especially in immunocompromised individuals. The growing incidence of this disorder, coupled with advances in diagnostic technologies and a heightened focus on treatment approaches, is anticipated to drive market expansion. The rise in PML cases among individuals with compromised immune systems, such as patients undergoing immunosuppressive therapies or those with autoimmune diseases, has highlighted an urgent need for effective treatment options.

In recent years, the development of innovative drug therapies, alongside increased awareness and early diagnosis efforts, has contributed to market growth. Pharmaceutical companies and research institutions are increasingly investing in the development of advanced therapeutic solutions for PML, which holds promise for enhancing treatment outcomes.

North America holds a dominant position in the market, attributed to its strong healthcare infrastructure and high investment in neurological research, while Asia Pacific is expected to witness significant growth owing to an increasing focus on healthcare advancements and rising awareness around neurological disorders.

As the healthcare industry continues to prioritize treatment options for rare neurological diseases, the global PML treatment market is well-positioned for further advancements and growth. Key industry players are likely to focus on strategic partnerships, research and development, and patient-centered approaches to support the effective management and treatment of progressive multifocal leukoencephalopathy.

Key Takeaways from the Market Study

• From 2018 to 2022, the Progressive Multifocal Leukoencephalopathy Treatment market grew at a CAGR of 2%.
• The global Progressive Multifocal Leukoencephalopathy Treatment market is expected to grow with a 3% CAGR during 2023 to 2033.
• As of 2033, the Progressive Multifocal Leukoencephalopathy Treatment Market is expected to reach US$ 1773.97 Million.
• According to the FMI analysis, hospital pharmacies account for the largest market share.
• North America is expected to possess 40% market share for the Progressive Multifocal Leukoencephalopathy Treatment market.
• The South and East Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering progressive multifocal leukoencephalopathy treatment.” says an FMI analyst

2018 to 2022 Progressive Multifocal Leukoencephalopathy Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for progressive multifocal leukoencephalopathy treatment reflected a value of 2% during the historical period, 2018 to 2022.

The market for Progressive Multifocal Leukoencephalopathy Treatment is gaining prominence as it is considered a rare, life-threatening brain disease caused by the JC virus. Furthermore, due to the rarity of the disease, there is ongoing research into developing new treatments for PML, expected to drive demand for these treatments.

The development of new PML treatments is a high priority for the medical community due to the devastating effects of the disease and the limited treatment options available. As more effective treatments become available, the market for PML treatment is likely to grow. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of Progressive Multifocal Leukoencephalopathy Treatments is fuelling the market growth. Thus, the market for progressive multifocal leukoencephalopathy treatment is expected to register a CAGR of 3% in the forecast period 2023 to 2033.

Market Competition

Key players in the market include pharmaceutical companies such as NeoImmuneTech, Neurimmune, GlaxoSmithKline Plc, Sanofi S.A., Gilead Sciences, Inc., Allergan Plc., Novartis AG, AbbVie Inc., and Bristol-Myers Squibb Company along with healthcare providers and technology companies among other global players.

• In October 2022, Cellevolve Bio, Inc., a company focused on developing and commercializing cell therapies, announced that its Investigational New Drug (IND) application for CE-VST01-JC has been approved by the USA Food and Drug Administration (FDA). CE-VST01-JC is a JC Virus Specific T Cell Therapy that is being studied for the treatment of progressive multifocal leukoencephalopathy (PML) and has received orphan drug designation from the FDA. The safety and effectiveness of CE-VST01-JC will be tested in a global, multi-center, randomized, double-blind, placebo-controlled Phase 2 study called ASCEND-JC. The study is expected to enroll up to 60 patients across the USA, Canada, and EU, with the first patient enrollment anticipated in the first half of 2023.
• In June 2021, Teserpaturev received conditional and temporary marketing approval in Japan for the treatment of malignant glioma, based on the results of a Japanese phase 2 clinical trial in patients with GBM. The trial showed that 92% of patients who received Teserpaturev immunotherapy treatment were still alive after one year, which is significantly higher than the typical 15% one-year survival rate in this group of patients receiving standard late-stage brain tumor treatments.

Key Companies Profiled

• NeoImmuneTech
• Inhibikase Therapeutics
• Neurimmune
• Pfizer Inc.
• GSK Plc
• Sanofi S.A.
• Gilead Sciences Inc.
• Allergan Plc.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Bristol-Myers Squibb Company

Key Segments Profiled in the Progressive Multifocal Leukoencephalopathy Treatment Industry Survey

Treatment:

• Anti-retroviral Therapy
• Antiviral/Anti JCV
• Other Symptomatic

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Indication:

• HIV/AIDS
• Organ Transplantation
• Multiple Sclerosis
• Hematologic Malignancies

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube